Iovance Biotherapeutics Inc
NASDAQ:IOVA
Intrinsic Value
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. [ Read More ]
The intrinsic value of one
IOVA
stock under the Base Case scenario is
18.02
USD.
Compared to the current market price of 10.91 USD,
Iovance Biotherapeutics Inc
is
Undervalued by 39%.
Iovance Biotherapeutics Inc's market capitalization is 3.1B USD.
IOVA stock price is 10.91 USD.
IOVA stock price (10.91 USD) is 39% less than its Intrinsic Value (18.02 USD).
IOVA. Open DCF Valuation
IOVA stock price (10.91 USD) is 39% less than its Relative Value (18.02 USD). Open Relative Valuation
IOVA has upside potential of 143% compared to the average analyst price target.
Open Wall St Estimates
IOVA's ROE (Return on Equity) has decreased in the last 3 years from -60% to -67%, and is approaching profitability.
IOVA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -304% to -141%, and is approaching profitability.
IOVA has negative Operating Income for the last twelve months.
IOVA has negative Net Income for the last twelve months.
IOVA's ROE (Return on Equity) for the past 12 months is negative and is equal to -67%.
IOVA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -141%.
IOVA has negative Gross Profit for the last twelve months.
IOVA's Revenue is forecast to grow at a rate of 724% per year over the next 3 years.
IOVA has negative Free Cash Flow for the last twelve months.
IOVA's D/E (Debt to Equity) is very low and is equal to 0.
IOVA has negative three-year average ROE (Return on Equity): -64%. The company is not efficient at transforming stockholders' equity into net income.
IOVA has negative three-year average ROIC (Return on Invested Capital): -199%. The company is not efficient at using invested capital to generate operating income.
IOVA's short-term assets (386m USD) exceed its short-term liabilties (83m USD).
IOVA's long-term assets (870m USD) exceed its long-term liabilties (190m USD).
IOVA has negative Net Debt. This means that the company has more cash and short-term investments (356m USD) than debt (1m USD).
IOVA's Altman Z-Score is very high and is equal to 7.84.
Valuation Backtest
Iovance Biotherapeutics Inc
Run backtest to discover the historical profit from buying and selling
IOVA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Iovance Biotherapeutics Inc
Balance Sheet Decomposition
Iovance Biotherapeutics Inc
| Current Assets | 385.5m |
| Cash & Short-Term Investments | 356.2m |
| Receivables | 234k |
| Other Current Assets | 29.1m |
| Non-Current Assets | 484.3m |
| PP&E | 183.3m |
| Intangibles | 294.3m |
| Other Non-Current Assets | 6.7m |
| Current Liabilities | 83.2m |
| Accounts Payable | 25.7m |
| Accrued Liabilities | 57.5m |
| Non-Current Liabilities | 106.6m |
| Long-Term Debt | 1m |
| Other Non-Current Liabilities | 105.6m |
Earnings Waterfall
Iovance Biotherapeutics Inc
|
Revenue
|
1.9m
USD
|
|
Cost of Revenue
|
-18m
USD
|
|
Gross Profit
|
-16.1m
USD
|
|
Operating Expenses
|
-451.3m
USD
|
|
Operating Income
|
-467.4m
USD
|
|
Other Expenses
|
17.8m
USD
|
|
Net Income
|
-449.6m
USD
|
Free Cash Flow Analysis
Iovance Biotherapeutics Inc
IOVA Profitability Score
Profitability Due Diligence
Iovance Biotherapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Iovance Biotherapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
IOVA Solvency Score
Solvency Due Diligence
Iovance Biotherapeutics Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Iovance Biotherapeutics Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IOVA Price Targets Summary
Iovance Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for
IOVA
is 26.52 USD
with a low forecast of 19.19 USD and a high forecast of 35.7 USD.
Ownership
IOVA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
IOVA Price
Iovance Biotherapeutics Inc
| Average Annual Return | 23.37% |
| Standard Deviation of Annual Returns | 104.61% |
| Max Drawdown | -94% |
| Market Capitalization | 3.1B USD |
| Shares Outstanding | 279 310 000 |
| Percentage of Shares Shorted | 19.96% |
IOVA News
Last Important Events
Iovance Biotherapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Iovance Biotherapeutics Inc
Company Profile
Iovance Biotherapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 319 full-time employees. The company went IPO on 2008-06-20. The firm is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The company has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer (NSCLC). In addition, the Company is investigating the combinations of TIL therapy with immune checkpoint inhibitors (ICIs) in metastatic melanoma, cervical cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). The company is investigating peripheral blood lymphocyte (PBL) therapy for patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Contact
IPO
Employees
Officers
The intrinsic value of one
IOVA
stock under the Base Case scenario is
18.02
USD.
Compared to the current market price of 10.91 USD,
Iovance Biotherapeutics Inc
is
Undervalued by 39%.
You don't have any saved screeners yet
